BACKGROUND: Ureaplasma respiratory tract colonization is a risk factor for bronchopulmonary dysplasia (BPD) in preterm infants, but whether Ureaplasma isolates from colonized infants can form biofilms is unknown. We hypothesized that Ureaplasma isolates vary in capacity to form biofilms that contribute to their antibiotic resistance and ability to evade host immune responses. Study objectives were to (1) determine the ability of Ureaplasma isolates from preterm neonates to form biofilms in vitro; (2) compare the susceptibility of the sessile and planktonic organisms to azithromycin (AZI) and erythromycin; and (3) determine the relationship of biofilm-forming capacity in Ureaplasma isolates and the risk for BPD. METHODS: Forty-three clinical isolates from preterm neonates and 5 American Tissue Culture Collection strains were characterized for their capacity to form biofilms in vitro, and antibiotic susceptibility was performed on each isolate prebiofilm and postbiofilm formation. RESULTS: Forty-one (95%) clinical and 4 of 5 (80%) American Tissue Culture Collection isolates formed biofilms. All isolates were more susceptible to AZI (minimum inhibitory concentration, MIC50 2 µg/mL) than erythromycin (MIC50 4 µg/mL), and biofilm formation did not significantly affect antibiotic susceptibility for the 2 tested antibiotics. The MIC50 and minimum biofilm inhibitory concentrations (MBIC50) for Ureaplasma urealyticum clinical isolates for AZI were higher than for MIC50 and MBIC50 for Ureaplasma parvum isolates. There were no differences in MIC or MBICs among isolates from BPD infants and non-BPD infants. CONCLUSIONS: Capacity to form biofilms is common among Ureaplasma spp. isolates, but biofilm formation did not impact MICs for AZI or erythromycin.
BACKGROUND:Ureaplasma respiratory tract colonization is a risk factor for bronchopulmonary dysplasia (BPD) in preterm infants, but whether Ureaplasma isolates from colonized infants can form biofilms is unknown. We hypothesized that Ureaplasma isolates vary in capacity to form biofilms that contribute to their antibiotic resistance and ability to evade host immune responses. Study objectives were to (1) determine the ability of Ureaplasma isolates from preterm neonates to form biofilms in vitro; (2) compare the susceptibility of the sessile and planktonic organisms to azithromycin (AZI) and erythromycin; and (3) determine the relationship of biofilm-forming capacity in Ureaplasma isolates and the risk for BPD. METHODS: Forty-three clinical isolates from preterm neonates and 5 American Tissue Culture Collection strains were characterized for their capacity to form biofilms in vitro, and antibiotic susceptibility was performed on each isolate prebiofilm and postbiofilm formation. RESULTS: Forty-one (95%) clinical and 4 of 5 (80%) American Tissue Culture Collection isolates formed biofilms. All isolates were more susceptible to AZI (minimum inhibitory concentration, MIC50 2 µg/mL) than erythromycin (MIC50 4 µg/mL), and biofilm formation did not significantly affect antibiotic susceptibility for the 2 tested antibiotics. The MIC50 and minimum biofilm inhibitory concentrations (MBIC50) for Ureaplasma urealyticum clinical isolates for AZI were higher than for MIC50 and MBIC50 for Ureaplasma parvum isolates. There were no differences in MIC or MBICs among isolates from BPD infants and non-BPD infants. CONCLUSIONS: Capacity to form biofilms is common among Ureaplasma spp. isolates, but biofilm formation did not impact MICs for AZI or erythromycin.
Authors: Sahar M A Hassanein; Rania A El-Farrash; Hala M Hafez; Omayma M Hassanin; Noha A E Abd El Rahman Journal: J Matern Fetal Neonatal Med Date: 2012-05-03
Authors: K B Waites; T A Figarola; T Schmid; D M Crabb; L B Duffy; J W Simecka Journal: Diagn Microbiol Infect Dis Date: 1991 May-Jun Impact factor: 2.803
Authors: L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi Journal: Antimicrob Agents Chemother Date: 2014-11-10 Impact factor: 5.191
Authors: Allison N Dammann; Anna B Chamby; Andrew J Catomeris; Kyle M Davidson; Hervé Tettelin; Jan-Peter van Pijkeren; Kathyayini P Gopalakrishna; Mary F Keith; Jordan L Elder; Adam J Ratner; Thomas A Hooven Journal: PLoS Pathog Date: 2021-03-08 Impact factor: 6.823
Authors: Rose Marie Viscardi; Michael L Terrin; Laurence S Magder; Natalie L Davis; Susan J Dulkerian; Ken B Waites; Namasivayam Ambalavanan; David A Kaufman; Pamela Donohue; Deborah J Tuttle; Jorn-Hendrik Weitkamp; Hazem E Hassan; Natalie D Eddington Journal: Arch Dis Child Fetal Neonatal Ed Date: 2020-03-13 Impact factor: 5.747
Authors: James M Daubenspeck; Arthur H Totten; Jason Needham; Monica Feng; Mitchell F Balish; T Prescott Atkinson; Kevin Dybvig Journal: Front Microbiol Date: 2020-10-27 Impact factor: 5.640